메뉴 건너뛰기




Volumn 70, Issue 6, 2017, Pages 704-712

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

Author keywords

cardiovascular stress; galectin 3; high sensitivity troponin; N terminal pro B type natriuretic peptide; sodium glucose co transporter 2 inhibitor; soluble ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CANAGLIFLOZIN; GALECTIN 3; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; PLACEBO; TROPONIN I; ANTIDIABETIC AGENT; BRAIN NATRIURETIC PEPTIDE; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

EID: 85025091208     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.06.016     Document Type: Article
Times cited : (151)

References (33)
  • 1
    • 84957709696 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside
    • Mudaliar, S., Polidori, D., Zambrowicz, B., Henry, R.R., Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38 (2015), 2344–2353.
    • (2015) Diabetes Care , vol.38 , pp. 2344-2353
    • Mudaliar, S.1    Polidori, D.2    Zambrowicz, B.3    Henry, R.R.4
  • 2
    • 84994180780 scopus 로고    scopus 로고
    • Empagliflozin and progression of kidney disease in type 2 diabetes
    • Wanner, C., Inzucchi, S.E., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
    • (2016) N Engl J Med , vol.375 , pp. 323-334
    • Wanner, C.1    Inzucchi, S.E.2    Lachin, J.M.3
  • 3
    • 85037667185 scopus 로고    scopus 로고
    • Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
    • Available at: Accessed June 9, 2017
    • U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Available at: https://www.fda.gov/downloads/Drugs/…/Guidances/ucm071627.pdf, 2008 Accessed June 9, 2017.
    • (2008)
  • 4
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman, B., Wanner, C., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 5
    • 84975853831 scopus 로고    scopus 로고
    • CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis
    • Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
    • (2016) Diabetes Care , vol.39 , pp. 1108-1114
    • Ferrannini, E.1    Mark, M.2    Mayoux, E.3
  • 6
    • 84975840750 scopus 로고    scopus 로고
    • Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis
    • Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
    • (2016) Diabetes Care , vol.39 , pp. 1115-1122
    • Mudaliar, S.1    Alloju, S.2    Henry, R.R.3
  • 7
    • 84980320178 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications
    • Heerspink, H.J., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation 134 (2016), 752–772.
    • (2016) Circulation , vol.134 , pp. 752-772
    • Heerspink, H.J.1    Perkins, B.A.2    Fitchett, D.H.3    Husain, M.4    Cherney, D.Z.5
  • 9
    • 85025064312 scopus 로고    scopus 로고
    • Dapagliflozin attenuates diabetic cardiomyopathy and the activation of the NLRP3/ASC inflammasome in mice with type-2 diabetes: a glucose-lowering and SGLT-2 independent effect
    • Paper presented at: ACC 66th Annual Scientific Sessions and Expo; March 17, Washington, DC. Abstract 1162-244
    • Ye Y, Bajaj M, Birnbaum Y. Dapagliflozin attenuates diabetic cardiomyopathy and the activation of the NLRP3/ASC inflammasome in mice with type-2 diabetes: a glucose-lowering and SGLT-2 independent effect. Paper presented at: ACC 66th Annual Scientific Sessions and Expo; March 17, 2017; Washington, DC. Abstract 1162-244.
    • (2017)
    • Ye, Y.1    Bajaj, M.2    Birnbaum, Y.3
  • 10
    • 85045782665 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review
    • [Published correction appears in Cardiol Ther 2016;5:169.]
    • Kalra, S., Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review. Cardiol Ther 5 (2016), 161–168 [Published correction appears in Cardiol Ther 2016;5:169.].
    • (2016) Cardiol Ther , vol.5 , pp. 161-168
    • Kalra, S.1
  • 11
    • 84964507777 scopus 로고    scopus 로고
    • SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
    • [Published correction appears in Diabetologia 2016;59:1573–4.]
    • Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339 [Published correction appears in Diabetologia 2016;59:1573–4.].
    • (2016) Diabetologia , vol.59 , pp. 1333-1339
    • Sattar, N.1    McLaren, J.2    Kristensen, S.L.3    Preiss, D.4    McMurray, J.J.5
  • 12
    • 85019611136 scopus 로고    scopus 로고
    • Novel diabetes drugs and the cardiovascular specialist
    • Sattar, N., Petrie, M.C., Zinman, B., Januzzi, J.L. Jr., Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol 69 (2017), 2646–2656.
    • (2017) J Am Coll Cardiol , vol.69 , pp. 2646-2656
    • Sattar, N.1    Petrie, M.C.2    Zinman, B.3    Januzzi, J.L.4
  • 13
    • 84988649876 scopus 로고    scopus 로고
    • Established and emerging roles of biomarkers in heart failure clinical trials
    • e002528
    • Ibrahim, N.E., Gaggin, H.K., Konstam, M.A., Januzzi, J.L. Jr., Established and emerging roles of biomarkers in heart failure clinical trials. Circ Heart Fail, 9, 2016 e002528.
    • (2016) Circ Heart Fail , vol.9
    • Ibrahim, N.E.1    Gaggin, H.K.2    Konstam, M.A.3    Januzzi, J.L.4
  • 14
    • 84990052413 scopus 로고    scopus 로고
    • Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis
    • Willeit, P., Kaptoge, S., Welsh, P., et al., for the Natriuretic Peptides Studies Collaboration. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 840–849.
    • (2016) Lancet Diabetes Endocrinol , vol.4 , pp. 840-849
    • Willeit, P.1    Kaptoge, S.2    Welsh, P.3
  • 15
    • 85017227814 scopus 로고    scopus 로고
    • Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) trial
    • Cavender, M.A., White, W.B., Jarolim, P., et al. Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) trial. Circulation 135 (2017), 1911–1921.
    • (2017) Circulation , vol.135 , pp. 1911-1921
    • Cavender, M.A.1    White, W.B.2    Jarolim, P.3
  • 16
    • 85019737787 scopus 로고    scopus 로고
    • Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
    • Ferrannini, E., Baldi, S., Frascerra, S., et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 40 (2017), 771–776.
    • (2017) Diabetes Care , vol.40 , pp. 771-776
    • Ferrannini, E.1    Baldi, S.2    Frascerra, S.3
  • 17
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 853-862
    • Lambers Heerspink, H.J.1    de Zeeuw, D.2    Wie, L.3    Leslie, B.4    List, J.5
  • 18
    • 84994910800 scopus 로고    scopus 로고
    • Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed type 2 diabetes
    • Wang, Y., Xu, L., Yuan, L., et al. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed type 2 diabetes. Diabet Med 33 (2016), 1732–1736.
    • (2016) Diabet Med , vol.33 , pp. 1732-1736
    • Wang, Y.1    Xu, L.2    Yuan, L.3
  • 19
    • 84880543926 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
    • Bode, B., Stenlöf, K., Sullivan, D., Fung, A., Usiskin, K., Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 41 (2013), 72–84.
    • (2013) Hosp Pract , vol.41 , pp. 72-84
    • Bode, B.1    Stenlöf, K.2    Sullivan, D.3    Fung, A.4    Usiskin, K.5
  • 20
    • 84964240560 scopus 로고    scopus 로고
    • Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes
    • Bode, B., Stenlöf, K., Harris, S., et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab 17 (2015), 294–303.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 294-303
    • Bode, B.1    Stenlöf, K.2    Harris, S.3
  • 21
    • 85102332811 scopus 로고    scopus 로고
    • Nonparametric Statistical Methods
    • 2nd edition John Wiley & Sons, Inc. New York, NY
    • Hollander, M., Wolfe, D.A., Nonparametric Statistical Methods. 2nd edition, 1999, John Wiley & Sons, Inc., New York, NY.
    • (1999)
    • Hollander, M.1    Wolfe, D.A.2
  • 22
    • 84892407436 scopus 로고    scopus 로고
    • The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes
    • Hillis, G.S., Welsh, P., Chalmers, J., et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 37 (2014), 295–303.
    • (2014) Diabetes Care , vol.37 , pp. 295-303
    • Hillis, G.S.1    Welsh, P.2    Chalmers, J.3
  • 23
    • 84923448295 scopus 로고    scopus 로고
    • SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
    • Inzucchi, S.E., Zinman, B., Wanner, C., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12 (2015), 90–100.
    • (2015) Diab Vasc Dis Res , vol.12 , pp. 90-100
    • Inzucchi, S.E.1    Zinman, B.2    Wanner, C.3
  • 24
    • 84991712516 scopus 로고    scopus 로고
    • Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
    • Baartscheer, A., Schumacher, C.A., Wüst, R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60 (2017), 568–573.
    • (2017) Diabetologia , vol.60 , pp. 568-573
    • Baartscheer, A.1    Schumacher, C.A.2    Wüst, R.C.3
  • 25
    • 85017099681 scopus 로고    scopus 로고
    • Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
    • [E-pub ahead of print] Apr 8
    • Shi, X., Verma, S., Yun, J., et al. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?. Mol Cell Biochem, 2017 Apr 8 [E-pub ahead of print].
    • (2017) Mol Cell Biochem
    • Shi, X.1    Verma, S.2    Yun, J.3
  • 26
    • 84914154997 scopus 로고    scopus 로고
    • Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus
    • Sha, S., Polidori, D., Heise, T., et al. Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 16 (2014), 1087–1095.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 1087-1095
    • Sha, S.1    Polidori, D.2    Heise, T.3
  • 27
    • 84883591288 scopus 로고    scopus 로고
    • Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk
    • Glick, D., DeFilippi, C.R., Christenson, R., Gottdiener, J.S., Seliger, S.L., Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk. J Am Coll Cardiol HF 1 (2013), 353–360.
    • (2013) J Am Coll Cardiol HF , vol.1 , pp. 353-360
    • Glick, D.1    DeFilippi, C.R.2    Christenson, R.3    Gottdiener, J.S.4    Seliger, S.L.5
  • 28
    • 84870346842 scopus 로고    scopus 로고
    • Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study
    • Coglianese, E.E., Larson, M.G., Vasan, R.S., et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 58 (2012), 1673–1681.
    • (2012) Clin Chem , vol.58 , pp. 1673-1681
    • Coglianese, E.E.1    Larson, M.G.2    Vasan, R.S.3
  • 30
    • 84880924263 scopus 로고    scopus 로고
    • Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial
    • Neal, B., Perkovic, V., de Zeeuw, D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. Am Heart J 166 (2013), 217–223.e11.
    • (2013) Am Heart J , vol.166 , pp. 217-223.e11
    • Neal, B.1    Perkovic, V.2    de Zeeuw, D.3
  • 31
    • 85013890365 scopus 로고    scopus 로고
    • Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial
    • Neal, B., Perkovic, V., Matthews, D.R., et al., for the CANVAS-R Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19 (2017), 387–393.
    • (2017) Diabetes Obes Metab , vol.19 , pp. 387-393
    • Neal, B.1    Perkovic, V.2    Matthews, D.R.3
  • 32
    • 85020470639 scopus 로고    scopus 로고
    • Optimizing the analysis strategy for the CANVAS Program—a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials
    • Neal, B., Perkovic, V., Mahaffey, K.W., et al., for the CANVAS Program Collaborative Group. Optimizing the analysis strategy for the CANVAS Program—a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19 (2017), 926–935.
    • (2017) Diabetes Obes Metab , vol.19 , pp. 926-935
    • Neal, B.1    Perkovic, V.2    Mahaffey, K.W.3
  • 33
    • 85023777061 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • [E-pub ahead of print] Jun 12
    • Neal, B., Perkovic, V., Mahaffey, K.W., et al., for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017 Jun 12 [E-pub ahead of print].
    • (2017) N Engl J Med
    • Neal, B.1    Perkovic, V.2    Mahaffey, K.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.